SREBF1 and prostate adenocarcinoma: Modulating the expression of ACLY and FASN through SREBP1 affects de novo lipogenesis production in PRAD cells, promoting cell proliferation (109), which is consistent with the inhibitory effects observed upon ACLY knockdown in NPC and PRAD that inhibit tumor cell migration and growth (102, 103).